Company profile
AIM ImmunoTech Inc.
AMEX:AIMBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| INTERFERON ALFA-N3 | approved | — | 0 | — |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (8)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT00215852 | phase2 | terminated | 2005-07-01 | 2009-04-01 | AIM ImmunoTech Inc. | A Randomized, Dose-ranging Study of Alferon LDO in Asymptomatic HIV+ Subjects |
| NCT05494697 | phase2 | suspended | 2027-08-01 | 2031-02-01 | AIM ImmunoTech Inc. | Ampligen Combined With SOC Versus SOC Alone Following First-Line Therapy in Subjects With LAPC |
| NCT01591473 | phase1_2 | terminated | 2012-04-01 | 2014-09-01 | AIM ImmunoTech Inc. | Safety Study of FluMist With and Without Ampligen |
| NCT00035581 | phase2 | terminated | 2001-05-01 | 2005-09-01 | AIM ImmunoTech Inc. | Safety and Efficacy of Ampligen in the Treatment of HIV Patients Failing HAART |
| NCT00215826 | phase2 | completed | 2004-11-01 | 2006-04-01 | AIM ImmunoTech Inc. | Study of Alferon® LDO (Low Dose Oral) in Normal Volunteers |
FDA applications (1)
| Application | Type | Applicant | Products | |||
|---|---|---|---|---|---|---|
| BLA 103158 | BLA | AIM ImmunoTech Inc. | ||||
Loading… | ||||||